| 11. |
- Bergkvist, Anders, et al.
(author)
-
Surface interactions in the complex between cytochrome f and the E43Q/D44N and E59K/E60Q plastocyanin double mutants as determined by (1)H-NMR chemical shift analysis
- 2001
-
In: Protein Science. - : John Wiley & Sons. - 0961-8368 .- 1469-896X. ; 10:12, s. 2623-2626
-
Journal article (peer-reviewed)abstract
- A combination of site-directed mutagenesis and NMR chemical shift perturbation analysis of backbone and side-chain protons has been used to characterize the transient complex of the photosynthetic redox proteins plastocyanin and cytochrome f. To elucidate the importance of charged residues on complex formation, the complex of cytochrome f and E43Q/D44N or E59K/E60Q spinach plastocyanin double mutants was studied by full analysis of the (1)H chemical shifts by use of two-dimensional homonuclear NMR spectra. Both mutants show a significant overall decrease in chemical shift perturbations compared with wild-type plastocyanin, in agreement with a large decrease in binding affinity. Qualitatively, the E43Q/D44N mutant showed a similar interaction surface as wild-type plastocyanin. The interaction surface in the E59K/E60Q mutant was distinctly different from wild type. It is concluded that all four charged residues contribute to the affinity and that residues E59 and E60 have an additional role in fine tuning the orientation of the proteins in the complex.
|
|
| 12. |
- Bergkvist, B
(author)
-
Debiteringstillägg för fingerskarvat virke 1988
- 1987
-
Reports (other academic/artistic)abstract
- Rapporten innehåller en revidering av debiteringstillägg för fingerskarvat virke. Föregående beräkning rörande debiteringstillägg publicerades i april 1984. Uppgifter om kapacitet och aktuell produktion grundar sig på enkäter till företag med godkända fingerskarvningsanläggningar.
|
|
| 13. |
- Bergkvist, B
(author)
-
Kapacitet och produktion av fingerskarvat konstruktionsvirke 1976-1987
- 1988
-
Reports (other academic/artistic)abstract
- Redovisning av kapacitetsutnyttjandet och kostnadsläget för fingerskarvningsanläggningar mellan 1976 och 1987. Det gäller endast anläggningar som är godkända för fingerskarvning av konstruktionsvirke och som var i drift under 1987. Rapporten är ett komplement till Träteks rapport "Debiteringstillägg för fingerskarvat virke 1988".
|
|
| 14. |
- Bergkvist, B, et al.
(author)
-
Sågverkens kostnader analys och modellbeskrivning typsågverk 100.000 m3 år 1986
- 1988
-
Reports (other academic/artistic)abstract
- Rapporten presenterar en modell för att analysera kostnaderna i ett sågverk för sågat, skeppningstorrt virke. Modellen har testats i fyra verk med en produktion kring 100.000 m3 per år. I modellen bryts kostnader ner på varje funktion i verket, t ex timmersortering, kantverk, torkning och orderanskaffning, samt på viktiga kostnadsslag, t ex kapital, personal, underhåll, elektricitet m m. Modellen är värdefull för bl a budgetering, efterkalkyl och prisstrategi.
|
|
| 15. |
- Bergkvist, B, et al.
(author)
-
Sågverkens kostnader typsågverk 40.000 m3 år 1987 jämförelse mellan typsågverk 40.000 m3 och 100.000 m3 år 1987
- 1989
-
Reports (other academic/artistic)abstract
- Rapporten redovisar och analyserar detaljerat de kostnader ett sågverk i 40.000 m3-klassen har. Dessutom görs en intressant jämförelse av kostnaderna i sågverk i storleksklasserna 40.000 m3 och 100.000 m3, där anläggningarna utnyttjas i ett respektive två skift. Fyra företag av varje storlek har välvilligt ställt sitt material till vårt förfogande. Träteks modell för kostnadsanalysen redovisas i Träteks tidigare rapport I 8806039.
|
|
| 16. |
|
|
| 17. |
|
|
| 18. |
|
|
| 19. |
- Cluver, Catherine, et al.
(author)
-
Impact of fetal growth restriction on pregnancy outcome in women undergoing expectant management for preterm pre-eclampsia
- 2023
-
In: Ultrasound in Obstetrics and Gynecology. - 1469-0705 .- 0960-7692. ; 62:5, s. 660-667
-
Journal article (peer-reviewed)abstract
- Objectives: To assess whether coexisting fetal growth restriction (FGR) influences pregnancy latency among women with preterm pre-eclampsia undergoing expectant management. Secondary outcomes assessed were indication for delivery, mode of delivery and rate of serious adverse maternal and perinatal outcomes. Methods: We conducted a secondary analysis of the Pre-eclampsia Intervention (PIE) and the Pre-eclampsia Intervention 2 (PI2) trial data. These randomized controlled trials evaluated whether esomeprazole and metformin could prolong gestation of women diagnosed with pre-eclampsia between 26 and 32 weeks of gestation undergoing expectant management. Delivery indications were deteriorating maternal or fetal status, or reaching 34 weeks' gestation. FGR (defined by Delphi consensus) at the time of pre-eclampsia diagnosis was examined as a predictor of outcome. Only placebo data from PI2 were included, as the trial showed that metformin use was associated with prolonged gestation. All outcome data were collected prospectively from diagnosis of pre-eclampsia to 6 weeks after the expected due date. Results: Of the 202 women included, 92 (45.5%) had FGR at the time of pre-eclampsia diagnosis. Median pregnancy latency was 6.8 days in the FGR group and 15.3 days in the control group (difference 8.5 days; adjusted 0.49-fold change (95% CI, 0.33–0.74); P < 0.001). FGR pregnancies were less likely to reach 34 weeks' gestation (12.0% vs 30.9%; adjusted relative risk (aRR), 0.44 (95% CI, 0.23–0.83)) and more likely to be delivered for suspected fetal compromise (64.1% vs 36.4%; aRR, 1.84 (95% CI, 1.36–2.47)). More women with FGR underwent a prelabor emergency Cesarean section (66.3% vs 43.6%; aRR, 1.56 (95% CI, 1.20–2.03)) and were less likely to have a successful induction of labor (4.3% vs 14.5%; aRR, 0.32 (95% CI, 0.10–1.00)), compared to those without FGR. The rate of maternal complications did not differ significantly between the two groups. FGR was associated with a higher rate of infant death (14.1% vs 4.5%; aRR, 3.26 (95% CI, 1.08–9.81)) and need for intubation and mechanical ventilation (15.2% vs 5.5%; aRR, 2.97 (95% CI, 1.11–7.90)). Conclusion: FGR is commonly present in women with early preterm pre-eclampsia and outcome is poorer. FGR is associated with shorter pregnancy latency, more emergency Cesarean deliveries, fewer successful inductions and increased rates of neonatal morbidity and mortality. © 2023 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
|
|
| 20. |
- de Boniface, J., et al.
(author)
-
Omitting axillary dissection in breast cancer with sentinel-node metastases
- 2024
-
In: New England Journal of Medicine. - 0028-4793 .- 1533-4406. ; 390:13, s. 1163-1175
-
Journal article (peer-reviewed)abstract
- BACKGROUND Trials evaluating the omission of completion axillary-lymph-node dissection in patients with clinically node-negative breast cancer and sentinel-lymph-node metastases have been compromised by limited statistical power, uncertain nodal radiotherapy target volumes, and a scarcity of data on relevant clinical subgroups.METHODS We conducted a noninferiority trial in which patients with clinically node-negative primary T1 to T3 breast cancer (tumor size, T1, ≤20 mm; T2, 21 to 50 mm; and T3, >50 mm in the largest dimension) with one or two sentinel-node macrometastases (metastasis size, >2 mm in the largest dimension) were randomly assigned in a 1:1 ratio to completion axillary-lymph-node dissection or its omission (sentinel-node biopsy only). Adjuvant treatment and radiation therapy were used in accordance with national guidelines. The primary end point was overall survival. We report here the per-protocol and modified intention-to-treat analyses of the prespecified secondary end point of recurrence-free survival. To show noninferiority of sentinel-node biopsy only, the upper boundary of the confidence interval for the hazard ratio for recurrence or death had to be below 1.44.RESULTS Between January 2015 and December 2021, a total of 2766 patients were enrolled across five countries. The per-protocol population included 2540 patients, of whom 1335 were assigned to undergo sentinel-node biopsy only and 1205 to undergo completion axillary-lymph-node dissection (dissection group). Radiation therapy including nodal target volumes was administered to 1192 of 1326 patients (89.9%) in the sentinel-node biopsy–only group and to 1058 of 1197 (88.4%) in the dissection group. The median follow-up was 46.8 months (range, 1.5 to 94.5). Overall, 191 patients had recurrence or died. The estimated 5-year recurrence-free survival was 89.7% (95% confidence interval [CI], 87.5 to 91.9) in the sentinel-node biopsy–only group and 88.7% (95% CI, 86.3 to 91.1) in the dissection group, with a country-adjusted hazard ratio for recurrence or death of 0.89 (95% CI, 0.66 to 1.19), which was significantly (P<0.001) below the prespecified noninferiority margin.CONCLUSIONS The omission of completion axillary-lymph-node dissection was noninferior to the more extensive surgery in patients with clinically node-negative breast cancer who had sentinel-node macrometastases, most of whom received nodal radiation therapy. (Funded by the Swedish Research Council and others; SENOMAC ClinicalTrials.gov number, NCT02240472.).
|
|
